Science & Technology

Phase 0/I dose escalation trial of MT-125 monotherapy in recurrent high-grade gliomas

Department of Health and Human Services — National Institutes of Health

Opportunity #: 2R44CA278293-04

Award Ceiling

$3.2M

Award Floor

$3.2M

Close Date

Jul 31, 2027

503 days left

Total Funding

$3.2M

Expected Awards

Posted Date

Aug 8, 2025

Cost Sharing Required

Grants.gov ID

sbir-2R44CA278293-04

Description

SBIR Phase Phase II award: "Phase 0/I dose escalation trial of MT-125 monotherapy in recurrent high-grade gliomas" awarded to MYOSIN THERAPEUTICS INC in JUPITER, Florida. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $3,157,209. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.

Eligible Applicants

Small businesses, Women-owned businesses

Apply on Grants.gov

Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.

View on Grants.gov

Disclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.